Cargando…

EMT, CTCs and CSCs in tumor relapse and drug-resistance

Tumor relapse and metastasis are the primary causes of poor survival rates in patients with advanced cancer despite successful resection or chemotherapeutic treatment. A primary cause of relapse and metastasis is the persistence of cancer stem cells (CSCs), which are highly resistant to chemotherapy...

Descripción completa

Detalles Bibliográficos
Autores principales: Mitra, Abhisek, Mishra, Lopa, Li, Shulin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4484413/
https://www.ncbi.nlm.nih.gov/pubmed/25986923
_version_ 1782378658522988544
author Mitra, Abhisek
Mishra, Lopa
Li, Shulin
author_facet Mitra, Abhisek
Mishra, Lopa
Li, Shulin
author_sort Mitra, Abhisek
collection PubMed
description Tumor relapse and metastasis are the primary causes of poor survival rates in patients with advanced cancer despite successful resection or chemotherapeutic treatment. A primary cause of relapse and metastasis is the persistence of cancer stem cells (CSCs), which are highly resistant to chemotherapy. Although highly efficacious drugs suppressing several subpopulations of CSCs in various tissue-specific cancers are available, recurrence is still common in patients. To find more suitable therapy for relapse, the mechanisms underlying metastasis and drug-resistance associated with relapse-initiating CSCs need to be identified. Recent studies in circulating tumor cells (CTCs) of some cancer patients manifest phenotypes of both CSCs and epithelial-mesenchymal transition (EMT). These patients are unresponsive to standard chemotherapies and have low progression free survival, suggesting that EMT-positive CTCs are related to co-occur with or transform into relapse-initiating CSCs. Furthermore, EMT programming in cancer cells enables in the remodeling of extracellular matrix to break the dormancy of relapse-initiating CSCs. In this review, we extensively discuss the association of the EMT program with CTCs and CSCs to characterize a subpopulation of patients prone to relapses. Identifying the mechanisms by which EMT-transformed CTCs and CSCs initiate relapse could facilitate the development of new or enhanced personalized therapeutic regimens.
format Online
Article
Text
id pubmed-4484413
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-44844132015-07-10 EMT, CTCs and CSCs in tumor relapse and drug-resistance Mitra, Abhisek Mishra, Lopa Li, Shulin Oncotarget Review Tumor relapse and metastasis are the primary causes of poor survival rates in patients with advanced cancer despite successful resection or chemotherapeutic treatment. A primary cause of relapse and metastasis is the persistence of cancer stem cells (CSCs), which are highly resistant to chemotherapy. Although highly efficacious drugs suppressing several subpopulations of CSCs in various tissue-specific cancers are available, recurrence is still common in patients. To find more suitable therapy for relapse, the mechanisms underlying metastasis and drug-resistance associated with relapse-initiating CSCs need to be identified. Recent studies in circulating tumor cells (CTCs) of some cancer patients manifest phenotypes of both CSCs and epithelial-mesenchymal transition (EMT). These patients are unresponsive to standard chemotherapies and have low progression free survival, suggesting that EMT-positive CTCs are related to co-occur with or transform into relapse-initiating CSCs. Furthermore, EMT programming in cancer cells enables in the remodeling of extracellular matrix to break the dormancy of relapse-initiating CSCs. In this review, we extensively discuss the association of the EMT program with CTCs and CSCs to characterize a subpopulation of patients prone to relapses. Identifying the mechanisms by which EMT-transformed CTCs and CSCs initiate relapse could facilitate the development of new or enhanced personalized therapeutic regimens. Impact Journals LLC 2015-05-08 /pmc/articles/PMC4484413/ /pubmed/25986923 Text en Copyright: © 2015 Mitra et al. http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Review
Mitra, Abhisek
Mishra, Lopa
Li, Shulin
EMT, CTCs and CSCs in tumor relapse and drug-resistance
title EMT, CTCs and CSCs in tumor relapse and drug-resistance
title_full EMT, CTCs and CSCs in tumor relapse and drug-resistance
title_fullStr EMT, CTCs and CSCs in tumor relapse and drug-resistance
title_full_unstemmed EMT, CTCs and CSCs in tumor relapse and drug-resistance
title_short EMT, CTCs and CSCs in tumor relapse and drug-resistance
title_sort emt, ctcs and cscs in tumor relapse and drug-resistance
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4484413/
https://www.ncbi.nlm.nih.gov/pubmed/25986923
work_keys_str_mv AT mitraabhisek emtctcsandcscsintumorrelapseanddrugresistance
AT mishralopa emtctcsandcscsintumorrelapseanddrugresistance
AT lishulin emtctcsandcscsintumorrelapseanddrugresistance